FCF Life Sciences

By integrating industry and investment banking expertise, we offer our clients bespoke financing strategies

Strategic Financing Advisory in Life Sciences

R&D-focused companies are in the DNA of FCF. Life Sciences is therefore a natural fit as one of our focus areas. Companies in this sector have unique financing requirements and must be addressed individually. For this reason, we have formed a team of highly diverse industry and investment banking experts to develop and execute the best individualized financing strategies for our Healthcare clients. The combined experience and skill set allows us to tackle every angle in the translation of a great technology into a sound financing story.

We work with innovative European Life Sciences companies with cutting-edge technologies from sectors such as:

  • Biotechnoloy
  • Medical Technology
  • Health Technology (IT)

We thrive to address all aspects of the financing challenges, that companies face from the seed to the commercialisation phase. We consider the long-term financing strategy as an important success factor, rather than focusing only on the next financing round. Part of this approach is to explore financing options on a regional and international scale and the combination of all available financing instruments:

  • Venture Capital
  • Equity-Linked Structures
  • Growth / Venture Debt
  • Off-Balance Financing

WHAT WE DO

At FCF Life Sciences, we develop bespoke financing strategies and support our clients throughout the entire fundraising process and beyond:

TEAM

Prof. Dr. Horst Domdey
Life Sciences Advisor

Arno Fuchs
Chief Executive Officer

Dr. Alexandra Goll
Life Sciences Advisor

Dr. Joachim M. Greuel
Life Sciences Advisor

Alexander Kuhn
Life Sciences Banking

Dr. Axel Polack
Life Sciences Advisor

Claus Schalper
Life Sciences Advisor

Dr. Mathias Schott
Head of Life Sciences

Sebastian Sommer
Life Sciences Banking

Enno Spillner
Life Sciences Advisor

FACTS & FIGURES

Experience
Over
100
years in aggregated Life Sciences experience
Leading Advisor Financing
Over
EUR 2bn
and 80 Life Sciences transactions aggregated
Contacts
Access to
>1.000
international investors
Team Professionals
Largest

European Life Sciences team specialised in pre-IPO financing

Research
4
regularly published Life Sciences reports

PREFERRED PARTNERS

UPCOMING EVENT

SELECTED TRANSACTIONS

Immunic AG

EIB Debt Facility
October 2020
€ 25 million
vasopharm_logo

Vasopharm GmbH

Transaction Support
July 2019
[amount confidential]
Logo_MP_AMW

AMW GmbH

EIB Debt Facility
November 2017
€ 25 million
numares transaction

numares AG

Capital Increase
November 2017
€ 11 million
MagForce

MagForce AG

EIB Debt Facility
August 2017
€ 35 million

LIFE SCIENCES RESEARCH SERIES

We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our FCF Life Sciences Research Series focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:

NEWS & PRESS

Scroll Up